Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Deffered Revenue: 2015-2020

Historic Non-Current Deffered Revenue for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Dec 2020 value amounting to $11.6 million.

  • Syndax Pharmaceuticals' Non-Current Deffered Revenue fell 12.25% to $10.9 million in Q2 2021 from the same period last year, while for Jun 2021 it was $10.9 million, marking a year-over-year decrease of 12.25%. This contributed to the annual value of $11.6 million for FY2020, which is 11.54% down from last year.
  • Syndax Pharmaceuticals' Non-Current Deffered Revenue amounted to $11.6 million in FY2020, which was down 11.54% from $13.1 million recorded in FY2019.
  • In the past 5 years, Syndax Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $16.8 million in FY2017 and a low of $11.6 million during FY2020.
  • Its 3-year average for Non-Current Deffered Revenue is $13.1 million, with a median of $13.1 million in 2019.
  • In the last 5 years, Syndax Pharmaceuticals' Non-Current Deffered Revenue increased by 17.86% in 2017 and then declined by 12.58% in 2018.
  • Over the past 5 years, Syndax Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $14.2 million in 2016, then increased by 17.86% to $16.8 million in 2017, then dropped by 12.58% to $14.7 million in 2018, then declined by 10.35% to $13.1 million in 2019, then declined by 11.54% to $11.6 million in 2020.